Aquestive Therapeutics, Inc. AQST Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s accrued expenses?
- Aquestive Therapeutics, Inc. (AQST) reported accrued expenses of $2.07M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Aquestive Therapeutics, Inc.'s accrued expenses decreased by 5.5% year-over-year, from $2.19M to $2.07M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s accrued expenses has grown at a -15.4% compound annual growth rate (CAGR), from $8.57M to $3.71M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.